
Marla Lipsyc-Sharf, MD
Languages
Education
Fellowship
Degrees
Residency
Board Certification
Contact Information
Scientific Interests
Dr. Lipsyc-Sharf's clinical-translational research is focused on circulating biomarkers, in particular circulating tumor DNA (ctDNA), for monitoring of patients' breast cancers and their treatment. Clinically, she focuses on the treatment and study of hormone receptor positive breast cancers and breast cancers in young women.
Highlighted Publications
Lipsyc-Sharf M, De Bruin EC, Santos K, et al. Circulating tumor DNA (ctDNA) and late recurrence in high-risk hormone receptor-positive, HER2- negative breast cancer. J Clin Oncol. 2022 Jun 4:JCO2200908. doi: 10.1200/JCO22.00908. Epub ahead of print. PMID: 35658506.
Goyette MA*, Lipsyc-Sharf M*, Polyak K. Clinical and translational relevance of intratumor heterogeneity. Trends Cancer. 2023 May 27:S2405-8033(23)00084-5. doi: 10.1016/j.trecan.2023.05.001. Epub ahead of print. PMID: 37248149. *Equal Contribution
Lipsyc-Sharf M, Tolaney SM. Elacestrant: who are optimal candidates for the first oral SERD? Ann Oncol. 2023 May;34(5):449-451. doi: 10.1016/j.annonc.2023.02.006. Epub 2023 Feb 20. PMID: 36813113.
Lipsyc-Sharf M, Jain E, Collins LC, et al. Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. JCO Precis Oncol. 2023 Jun;7:e2300076. doi: 10.1200/PO.23.00076. PMID: 37364233.
Lipsyc-Sharf M, Partridge AH. Fertility and Sexual Health in Young Women with Early-Stage Breast Cancer. Surgical Oncology Clinics of North America, 2023, ISSN 1055-3207, https://doi.org/10.1016/j.soc.2023.05.012.